Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study

Brian D Rankin; Jorge-Ryan Georgakopoulos; Muskaan Sachdeva; Asfandyar Mufti; Alim R Devani; Melinda J Gooderham; Chih-Ho Hong; Vipul Jain; Perla Lansang; Ronald Vender; Jensen Yeung; Vimal H Prajapati

doi:10.1080/09546634.2022.2036673

Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study

J Dermatolog Treat. 2022 Aug;33(5):2692-2694. doi: 10.1080/09546634.2022.2036673. Epub 2022 Apr 21.

Authors

Brian D Rankin¹, Jorge-Ryan Georgakopoulos², Muskaan Sachdeva³, Asfandyar Mufti², Alim R Devani^{4

5

6}, Melinda J Gooderham^{7

8

9}, Chih-Ho Hong^{10

11}, Vipul Jain^{12

13

14

15}, Perla Lansang^{2

16

17}, Ronald Vender^{18

19}, Jensen Yeung^{2

16

17

20}, Vimal H Prajapati^{4

5

6

21

22

23}

Affiliations

¹ Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
² Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ Dermatology Research Institute, Calgary, Alberta, Canada.
⁵ Skin Health & Wellness Centre, Calgary, Alberta, Canada.
⁶ Probity Medical Research, Calgary, Alberta, Canada.
⁷ Queen's University, Kingston, Ontario, Canada.
⁸ SKiN Centre for Dermatology, Peterborough, Ontario, Canada.
⁹ Probity Medical Research, Peterborough, Ontario, Canada.
¹⁰ Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
¹¹ Dr. Chih-Ho Hong Medical Inc, Surrey, British Columbia, Canada.
¹² Division of Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.
¹³ Niagara Region Medical, Niagara Falls, Ontario, Canada.
¹⁴ Allergy Research Canada Inc, Niagara Falls, Ontario, Canada.
¹⁵ Probity Medical Research, Niagara Falls, Ontario, Canada.
¹⁶ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
¹⁷ Section of Paediatric Dermatology, Department of Paediatric Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.
¹⁸ Department of Dermatology, McMaster University, Hamilton, Ontario, Canada.
¹⁹ Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, Ontario, Canada.
²⁰ Probity Medical Research Inc, Waterloo, Ontario, Canada.
²¹ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
²² Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
²³ Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.

PMID: 35446185
DOI: 10.1080/09546634.2022.2036673

No abstract available

Publication types

Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19*
Humans
Incidence
Prognosis
Retrospective Studies
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
dupilumab